FSTL3 and cardiac hypertrophy: Inhibiting FSTL3 by neutralizing antibodies may be a potential therapeutic strategy for minimizing its deleterious effects on cardiomyocytes and fibroblasts, thereby inhibiting the development of cardiac hypertrophy and myocardial fibrosis (Bartholin et al., 2002; Panse et al., 2012).